Sargramostim (GM-CSF) + PD-1

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 16, 2021

Primary Completion Date

June 10, 2024

Study Completion Date

June 9, 2025

Conditions
Unresectable MelanomaMetastatic MelanomaStage III MelanomaStage IV Melanoma
Interventions
DRUG

Sargramostim (GM-CSF)

Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.

DRUG

Pembrolizumab (anti-PD-1)

Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion

Sponsors
All Listed Sponsors
collaborator

Partner Therapeutics (PTx)

UNKNOWN

lead

Dana-Farber Cancer Institute

OTHER